कंपनी का अवलोकन
vTv Therapeutics Inc. operates as a late-stage biopharmaceutical entity dedicated to the development of oral small molecule drug candidates designed to address conditions affecting patients with diabetes and other chronic diseases. The organization functions within the healthcare sector, specifically under the biotechnology industry, where the primary focus is on translating scientific research into therapeutics that can be administered orally rather than via injection. This enterprise currently maintains a market capitalization of $151.48M and employs a workforce of 26 individuals, reflecting a small-cap structure typical of early-to-mid stage biotech firms. The combination of a market cap in the mid-hundred-million dollar range and a revenue structure currently reported as N/A indicates that the company's valuation is driven primarily by asset potential and clinical pipeline progress rather than established commercial sales streams, a common characteristic for late-stage biopharmaceutical companies focused on specific therapeutic areas like diabetes.
वित्तीय स्वास्थ्य
The financial performance of vTv Therapeutics Inc. for the trailing twelve months reveals a net income of $-26,974,000 and an EBITDA of $-32,792,000, while the reported revenue is listed as N/A, necessitating an analysis of cost structures through the lens of cash burn. The significant negative net income relative to the reported N/A revenue figure suggests that the company is operating in a pre-revenue or minimal revenue generation phase, where operating expenses such as research and development, personnel costs, and regulatory compliance costs are substantially exceeding any current income streams. The company reported a free cash flow of $-14,697,750, indicating that it is consuming cash reserves to fund its operations and drug development activities, which limits immediate financial flexibility but is standard for capital-intensive biotechnology ventures. All three reported margins—gross margin, operating margin, and profit margin—are stated as 0.0%, a metric that reflects the absence of positive commercial revenue or the fact that current sales do not yet cover the high fixed costs associated with bringing a drug candidate like cadisegliatin (TTP399) to market. On the liability side, the company holds $88.93M in cash against $0 in debt, resulting in a debt-to-equity ratio of N/A, which portrays a highly conservative balance sheet structure with no leverage and substantial liquidity buffers available for strategic use. The current ratio stands at 13.54, a figure that demonstrates an exceptionally strong short-term liquidity position, implying that the company possesses more than thirteen times the current assets required to meet its short-term obligations without needing external financing. Return on Equity is reported at -78.9% and Return on Assets at -32.0%, metrics that indicate that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a situation typical for companies in the late-stage development phase before product approval and commercialization.
मूल्यांकन आकलन
Valuation metrics for vTv Therapeutics Inc. present a complex picture where traditional profitability multiples are not yet applicable due to the lack of earnings. The trailing P/E ratio is N/A because the company has not generated positive net income, while the forward P/E is reported as -10.33, a negative figure that arises from projecting continued losses rather than expected earnings growth in the near term. The price-to-book ratio is calculated at 7.41, suggesting that the market values the company's equity at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and the potential future value of its drug pipeline. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A due to the lack of reported revenue, and the EV/EBITDA stands at -11.84, which further confirms that the company is being valued based on non-earnings criteria rather than current profitability or sales generation. The stock has traded within a range defined by a 52-week high of $44.00 and a 52-week low of $14.00, meaning the current trading price sits at a level that reflects high volatility and significant distance from both the recent peak and the bottom of the annual trading range. The beta value is recorded at 0.40, indicating that the stock's price volatility is substantially lower than that of the broader market, suggesting that the share price is less sensitive to general market movements compared to larger-cap equities.
Growth & Income
The growth profile for vTv Therapeutics Inc. is characterized by revenue growth and earnings growth rates that are both reported as N/A, reflecting the company's stage in the development lifecycle where commercial sales have not yet materialized to generate comparable year-over-year statistics. Since the company is not currently paying dividends, the dividend yield is N/A and the payout ratio is 0.0%, which signifies that all available cash flows and earnings potential are being retained within the corporation to fund research, development, and clinical trial activities rather than being distributed to shareholders. The absence of a dividend policy implies a strategic decision to reinvest limited financial resources directly into the advancement of oral small molecule drug candidates and to sustain operations until the lead asset, cadisegliatin, achieves regulatory approval and generates commercial revenue. Consequently, the overall growth and income profile is defined by capital appreciation potential tied to clinical milestones rather than income generation through dividends or current earnings expansion, creating a high-risk, high-reward dynamic typical of late-stage biotechnology firms.